KNSA
Income statement / Annual
Last year (2023), Kiniksa Pharmaceuticals, Ltd.'s total revenue was $270.26 M,
an increase of 22.74% from the previous year.
In 2023, Kiniksa Pharmaceuticals, Ltd.'s net income was $14.08 M.
See Kiniksa Pharmaceuticals, Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$270.26 M
|
$220.18 M
|
$38.54 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$91.04 M |
$46.97 M |
$9.10 M |
$3.81 M |
$3.28 M |
$286,000.00 |
$28,000.00 |
$22,000.00 |
| Gross Profit |
$179.22 M |
$173.21 M |
$29.44 M |
-$3.81 M |
-$3.28 M |
-$286,000.00 |
-$28,000.00 |
-$22,000.00 |
| Gross Profit Ratio |
0.66 |
0.79 |
0.76 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$74.99 M
|
$65.49 M
|
$99.30 M
|
$112.04 M
|
$135.00 M
|
$86.60 M
|
$56.36 M
|
$17.44 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$34.96 M
|
$21.56 M
|
$9.04 M
|
$6.56 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$129.43 M
|
$97.95 M
|
$85.95 M
|
$45.32 M
|
$34.96 M
|
$21.56 M
|
$9.04 M
|
$6.56 M
|
| Other Expenses |
$8.54 M |
$1.25 M |
$835,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$204.42 M |
$163.44 M |
$186.08 M |
$157.36 M |
$169.96 M |
$108.16 M |
$65.40 M |
$24.00 M |
| Cost And Expenses |
$295.46 M |
$210.41 M |
$195.18 M |
$157.36 M |
$169.96 M |
$108.16 M |
$65.40 M |
$24.00 M |
| Interest Income |
$8.54 M |
$1.25 M |
$97,000.00 |
$1.13 M |
$6.05 M |
$4.72 M |
$529,000.00 |
$65,000.00 |
| Interest Expense |
$0.00 |
$1.25 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$2.11 M
|
$4.22 M
|
$4.09 M
|
$3.81 M
|
$3.28 M
|
$286,000.00
|
$28,000.00
|
$22,000.00
|
| EBITDA |
-$23.09 M
|
$9.77 M
|
-$156.64 M
|
-$157.36 M
|
-$169.96 M
|
-$108.16 M
|
-$65.37 M
|
-$23.98 M
|
| EBITDA Ratio |
-0.09 |
0.04 |
-4.06 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-0.09
|
0.03
|
-4.06
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$8.54 M
|
$3.66 M
|
$97,000.00
|
$1.13 M
|
$6.05 M
|
$4.72 M
|
$529,000.00
|
$65,000.00
|
| Income Before Tax |
-$16.65 M |
$11.03 M |
-$156.54 M |
-$156.23 M |
-$163.91 M |
-$103.44 M |
-$64.87 M |
-$23.94 M |
| Income Before Tax Ratio
|
-0.06
|
0.05
|
-4.06
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$30.74 M |
-$172.34 M |
$1.39 M |
$5.15 M |
-$2.05 M |
-$214,000.00 |
$2,000.00 |
$36,000.00 |
| Net Income |
$14.08 M |
$183.36 M |
-$157.92 M |
-$161.38 M |
-$161.87 M |
-$103.23 M |
-$64.87 M |
-$23.97 M |
| Net Income Ratio |
0.05 |
0.83 |
-4.1 |
0 |
0 |
0 |
0 |
0 |
| EPS |
0.2 |
2.64 |
-2.3 |
-2.61 |
-2.99 |
-3.49 |
-2 |
-0.74 |
| EPS Diluted |
0.2 |
2.6 |
-2.3 |
-2.61 |
-2.99 |
-3.49 |
-2 |
-0.74 |
| Weighted Average Shares
Out |
$70.06 M
|
$69.38 M
|
$68.58 M
|
$61.84 M
|
$54.05 M
|
$29.55 M
|
$32.47 M
|
$32.47 M
|
| Weighted Average Shares
Out Diluted |
$71.92 M
|
$70.42 M
|
$68.58 M
|
$61.84 M
|
$54.05 M
|
$29.55 M
|
$32.47 M
|
$32.47 M
|
| Link |
|
|
|
|
|
|
|
|
